Pediatric glomerular disease clinical trials are expanding globally as the newly launched GD-Kids initiative tackles persistent trial barriers, offering young patients specialized therapies previously restricted to adults.
Clinical Research Expands to Include Children in Glomerular Disease Trials
- Pediatric Glomerular Disease Trials: Clinical research is actively expanding to include children, moving past traditional adult-only study models.
- Overcoming Barriers: Investigators have disproved assumptions that distance, income, or family burden prevent pediatric trial participation and retention.
- Global Coordination: The newly formed GD-Kids working group unites international experts to drive equitable trial access across multiple continents.
Breaking Barriers in Pediatric Glomerular Trials
For years, the lack of clinical trials has restricted the evidence behind pediatric consensus treatment plans, according to Jeffrey Wenderfer, whose work centers on lupus nephritis. Khalid, who oversees a research facility dedicated to glomerular disorders at Riley, shared the story of a young participant who frequently inquired about when a medication tailored to her condition would become available.
Drawing on her IgA nephropathy trial experience, Khalid described several assumptions disproven in her clinic. Parents were not unwilling to enroll their children once trust was established.
“I realized it was important for me as their physician and for us as a community to teach people about the disease, to teach them about the science, to bring them to a place of trust in the physician team,” Khalid said.
Geographic separation proved to be no obstacle, given that the majority of her trial participants travel approximately a three-hour commute to reach her facility. Vulnerability indices such as income and household size did not predict participation, and retention has been strong.
Families value consistent coordinators, facilities, and physicians, which creates a routine and individualized care. Having initially anticipated that clinical studies would be perceived as an imposition, Khalid said that numerous relatives instead expressed appreciation for contributing to a larger cause.
Requirements specific to children were emphasized by Wenderfer, encompassing child assent, ongoing reassent as youngsters grow older, and the eventual transition to formal consent upon reaching the age of majority. Institutional review boards also apply added protections for children as a vulnerable population.
Expanding Global Access Through GD-Kids
Wenderfer said some trials now enroll children and adults together from the start. Alternatively, certain studies initiate pediatric enrollment only following a successful adult trial, frequently beginning with older adolescents prior to advancing to younger cohorts subsequent to an evaluation by a data safety monitoring board.
Khalid leads the PIONEER basket trial at Riley, which enrolls both children and adults with glomerular diseases. Beyond acting as site investigators, pediatric nephrologists can take on responsibilities such as protocol design, participation in data safety monitoring boards, and positions within the pharmaceutical and biotech sectors, as pointed out by Wenderfer.
Promoting equitable trial access in underrepresented regions is one of four core GD-Kids goals. According to Wenderfer, the coalition currently incorporates participants hailing from North America, Europe, Japan, Hong Kong, and India, alongside future intentions to reach into South America and Africa.
| Trial Initiative / Working Group | Key Focus Areas | Geographic Scope |
|---|---|---|
| GD-Kids Initiative | Advancing pediatric glomerular medicine and equitable trial access | North America, Europe, Japan, Hong Kong, India, with expansion planned |
| PIONEER Trial | Enrolling children and adults with glomerular diseases | Single-center pediatric initiative at Riley / IU School of Medicine |
Khalid said some newer agents may eventually allow clinicians to offer patients the prospect of disease elimination. Wenderfer said he hopes GD-Kids will draw more colleagues into clinical trial research.
Patients Must Meet Strict Exclusion Criteria
Pediatric patients with active systemic infections, uncontrolled comorbidities, or hypersensitivity to investigational agents specified in trial protocols must adhere strictly to exclusion criteria set by institutional review boards.
References
- International Society of Glomerular Disease. International Society of Glomerular Disease launches GD-Kids to advance pediatric glomerular medicine worldwide. Published October 15, 2026. Accessed November 14, 2026.
- Indiana University School of Medicine. First pediatric patient in the world enrolled in PIONEER clinical trial for kidney glomerular disease at IU School of Medicine. Published April 30, 2026. Accessed November 14, 2026.
Disclaimer: This article is intended for informational and educational purposes only and does not substitute for professional medical advice, diagnosis, or treatment.
